Browse Studies — Arctuva

Phase 3

A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS

The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year int…

Respiratory Syncytial Virus (RSV)

Estimated

~$10 – $7,500

PfizerNCT07768345

Phase 3

A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to \<18 years of age at high risk for RSV disease…

Respiratory Syncytial Virus (RSV)

Estimated

~$10 – $7,500

PfizerNCT07839871

CorEvitas RSV Vaccine Pregnancy Registry (RSV-PR)

The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infa…

Respiratory Syncytial Virus (RSV)

Estimated

~$10 – $7,500

CorEvitasNCT06521944

Phase 2

Immunogenicity and Safety of Multiple-Dose Adjuvanted RSVPreF3 (Arexvy®) Vaccination Among Immunocompromised Persons

This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with wea…

Respiratory Syncytial Virus (RSV)

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07050732